News and Trends 19 Oct 2022 Multi-year agreement to boost women’s reproductive health A multi-year agreement between BioSkryb Genomics and Cooper Genomics, a reproductive health company was announced yesterday (October 18). The agreement is to license BioSkyrb’s proprietary genomic amplification technology. Cooper will utilize the Bioskryb technology to enhance their preimplantation genetic testing (PGT) capabilities. The agreement will also allow Cooper to boost BioSkyrb’s tech for the PGT […] October 19, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 Progress of COPD drug boosted by debt financing of up to $150M Verona Pharma plc has today (October 17) announced that it has entered into a debt financing facility providing access of up to $150 million from Oxford Finance LLC. The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine, the company’s product candidate, which recently reported positive phase 3 data in the […] October 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 17 Oct 2022 Clinical trial of treatment for advanced solid tumors approved A clinical trial of a drug to treat advanced solid tumors has been approved by the National Medical Products Administration. China-based Akeso Inc., made the announcement on Sunday (October 16) about a phase 1b/2 clinical trial of its in-house developed Ivonescimab (PD-1/VEGF bi-specific AK112) combined with Drebuxelimab (CD73, AK119). AK112 is the first PD-1/VEGF bi-specific […] October 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 More positive news announced for Verona’s COPD treatment Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). The company focuses on respiratory diseases, and made the announcement today (October 14) about the positive analyses demonstrating how ensifentrine reduced exacerbation rates across subgroups in the trial. Ensifentrine is […] October 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Way to transform Cas-9 protein into spherical nuclear acid developed A team of researchers at U.S. Northwestern University has developed a way to transform the Cas-9 protein into a spherical nuclear acid (SNA). It can then be loaded with critical components as required to access a broad range of tissue and cell types, as well as the intracellular compartments required for gene editing. The team […] October 17, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022 Cytel signs agreement with two Scandinavian medicinal product companies U.S.-based Cytel Inc. has entered into an agreement to acquire Scandinavian companies SDS Life Sciences AB and SDS MedeQ AB. Cytel says the move will add new talent to the company’s strategic consulting group and bring additional capabilities for the development of drugs and medical devices. It says sponsors will also have easier access to […] October 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Plan launched to improve diversity of clinical trials Help to improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age and ethnicity has been revealed. Medidata, a Dassault Systèmes company, has launched the intelligent trials diversity module. The new module will help sponsors and clinical research organizations (CROs) benchmark the diversity of their trials and identify sites […] October 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Agreement to take advantage of stem cells from first teeth An agreement has been made to utilize the advantage of stem cells from human exfoliated deciduous teeth (SHED) under development by Japan-based Kidswell Bio. Kidswell is entering into the agreement with Showa Denko Materials Co., which will also enable process development as well as clinical manufacturing of cell therapy products. Under the terms of agreement, […] October 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Amphista Therapeutics and Domainex Ltd partner for integrated drug services Amphista Therapeutics Ltd., has selected Domainex Ltd as one of its trusted partners to provide integrated drug discovery services to support its research programs. The partnership will also advance its portfolio of drug discovery projects targeting protein degradation (TPD). Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to deal with disease-causing […] October 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Boston Cell Standards wins FDA $510K clearance for anatomic pathology controls A company standardizing cancer diagnostic tissue testing with the first immunohistochemistry (IHC) laboratory reference standards has received $510,000 clearance from the U.S. Food and Drug Administration (FDA). The money will go towards Boston Cell Standards IHControls panel for evaluating breast cancers. The clearance represents regulatory approval. “IHControls represent a giant step forward in standardization in […] October 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Novavax COVID-19 vaccine data supports homologous and heterologous boosting Data in from adults and adolescents aged 12-17 collected in a phase 3 trial of a prototype Novavax COVID-19 vaccine showed it had achieved its pre-specified immunologic endpoint. Study 307 met its primary endpoint, showing three lots of the vaccine tested as a heterologous booster induced consistent immune responses in previously vaccinated adults aged 18-49. […] October 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Agreement signed to advance therapy for autoimmune disease HanAll Biopharma’s licensed partner, Harbour BioMed, has signed an exclusive sublicense agreement with CSPC NBP Pharmaceutical Co., Ltd for an advanced inhibitor. The agreement is for HanAll’s neonatal Fc receptor (FcRn) inhibitor batoclimab which is one of the most advanced being developed in Greater China. The companies say it has the potential to become a […] October 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email